Investor Area

Home / Investor Area / News / CLINUVEL Newsletter
 

CLINUVEL Newsletter

 

In this News Communiqué VII, we pause to reflect on the outstanding US regulatory outcome and look back one last time at all the events which led to the long-desired outcome on 8 October, the Food and Drug Administration’s (FDA’s) approval of SCENESSE® (afamelanotide 16mg). […]

Download PDF